SciSparc (SPRC) Short term Debt (2018 - 2025)
SciSparc (SPRC) posted Short term Debt of $356000.0 for Q4 2025, up 95.6% sequentially from $182000.0 in Q2 2025, and down 91.57% YoY from $4.2 million in Q4 2024.
SciSparc (SPRC) Short term Debt (2018 - 2025) Analysis & Trends
SciSparc has reported Short term Debt for 5 years, with the latest figure at $356000.0 in Q4 2025.
- Quarterly Short term Debt fell 91.57% year-over-year to $356000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $356000.0 (down 91.57% YoY) and the FY2025 annual result came in at $356000.0, down 91.57% from the prior year.
- Short term Debt grew to $356000.0 in Q4 2025 per SPRC's latest filing, from $182000.0 in the prior quarter.
- Over five years, Short term Debt peaked at $4.2 million in Q4 2024 and troughed at $182000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.57 Bn | 131.72 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 86.71 Bn | 78.72 Bn | 3.93 Bn |
| 3 | Argenx Se | 65.44 Bn | 60.25 Bn | 1.37 Bn |
| 4 | Moderna | 60.06 Bn | 54.93 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 42.16 Bn | 37.06 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.89 Bn | 28.58 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.11 Bn | 9.72 Bn | 668.28 Mn |
| 8 | Insmed | 27.59 Bn | 26.43 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - |
| 10 | SciSparc | 807,202.50 | 807,202.50 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 356,000.00 |
| Jun 30, 2025 | 182,000.00 |
| Dec 31, 2024 | 4.22 Mn |
| Dec 31, 2020 | 188,000.00 |
| Jun 30, 2020 | 61,000.00 |
| Jun 30, 2019 | 993,000.00 |
| Dec 31, 2018 | 779,000.00 |